Pipeline
Two assets. Multiple indications. One mechanism.
Entolimod and its second-generation follow-on, Entolasta, together form a pipeline of innate immune modulating therapies being investigated across biodefense, oncology supportive care, and immuno-oncology. More than $140 million has been invested across the platform to date.
Development pipeline
The table below summarizes current development programs by asset, indication, and stage of development.
TLR5 platform: one receptor, multiple disease states
Targeted activation of the TLR5 receptor drives a coordinated biological response across multiple tissue systems — enabling one mechanism to address multiple clinical indications:
- Hematopoiesis — bone marrow recovery (neutrophils, platelets).
- GI protection — intestinal integrity after radiation injury or chemotherapy.
- NK / T-cell activation — anti-tumor immunity and immuno-oncology combination potential.
- Anti-apoptotic signaling — cell survival in bone marrow and GI tissues.
- Endothelial repair — vascular integrity after radiation exposure.
- Immune modulation — reversing immunosenescence (Mayo Clinic Phase II).
Development milestones
Anticipated development milestones across the next 18 to 24 months include:
- Initiation of Neutropenia clinical studies (timing subject to IND readiness)
- Entolasta IND-enabling studies
- Entolasta drug substance availability (targeted end of 2026)
- GMP Entolimod for bioequivalence study (targeted 1Q2027)
- Entolasta pre-IND meeting (targeted 1Q2027)
- GMP manufacturing validation activities (targeted 2027)
Milestone timing is subject to clinical, regulatory, and operational factors and may change. Entolasta is expected to be treated by FDA as a new molecular entity and will require its own clinical development program and regulatory submissions.
Market context
The TLR5 platform is being investigated across therapeutic areas with significant market potential, including Acute Radiation Syndrome (estimated $5.5B, 5.2% CAGR), Neutropenia and oncology supportive care (estimated $22.3B, 4.8% CAGR), and Immuno-Oncology solid tumors (estimated $120B, 16.3% CAGR). Market estimates are based on industry sources and do not reflect Valion Bio revenue projections.